AzTrials
AzTrials

Morbid ObesityPSICHENCT04643262

Sleeve Gastrectomy: Outcome, Morbidity and Mortality. A Multicentric Retrospective Trial

An observational study of Morbid Obesity, run by Azienda Sanitaria Locale Napoli 2 Nord.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Laparoscopic sleeve gastrectomy (LSG) is currently the most frequent primary bariatric procedure performed worldwide. LSG is a safe and effective technique in terms of excess weight loss and it is, moreover, a powerful metabolic operation that activates significant hormonal pathways that lead to changes in eating… Read more about this study

Who is it for?
Ages 18 to 68 yearsHealthy volunteers can take part
Conditions the study is for
Morbid Obesity
What is being tested?
Sleeve Gastrectomy
Type of treatment
Surgery or procedure
How many people
10,000 participants
Where
No sites listed yet
Study dates
1 Jan 2015to 30 Jun 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 68 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: This study is a retrospective multicenter trial conduct from January 2015 to December 2020 in 20 centers. All patients underwent Sleeve Gastrectomy. All the procedures were performed by the (---- number of surgeons). Morbid obesity was preoperatively diagnosed according to the International Federation for Surgery of Obesity (IFSO) guidelines

Who may be able to join

  • Morbid obesity defined as Body Mass Index 40 kg/m2
  • Body Mass Index >35 with comorbidity (Type 2 Mellitus Diabetes (T2MD), hypertension, hyperlipidemia, bronchial asthma, osteoarthritis))
  • Age between 25-68 years old.

Who cannot join

  • Patients with endocrine disorders causing obesity (as hypothyroidism and Cushing disease)
  • Pregnancy or lactation
  • Psychiatric illness
  • Recent diagnosis of malignancy
  • Inflammatory bowel disease
  • Barrett ́s esophagus

About this study

Official title: Sleeve Gastrectomy: Outcome, Morbidity and Mortality. A Multicentric Retrospective Trial. PSICHE TRIAL (Postoperative Sleevegastrectomy Italian or (International) Group Complications Highlights Experience)

Laparoscopic sleeve gastrectomy (LSG) is currently the most frequent primary bariatric procedure performed worldwide. LSG is a safe and effective technique in terms of excess weight loss and it is, moreover, a powerful metabolic operation that activates significant hormonal pathways that lead to changes in eating behavior, glycemic control and intestinal functions.Regarding a technical point of view, LSG might be considered a time saving procedure for the absence of intestinal anastomosis. The most frequent and sometimes dangerous complications are leaking, hemorrhage, splenic injury, stenosis and Gastro-Esophageal Reflux Disease (GERD). Despite its established efficacy and safety, dispute still exists on the optimal conduction of LSG operative technique: bougie size, distance of resection margin from the pylorus, the shape of section at the gastroesophageal junction, staple line reinforcement and intraoperative leak testing are among the most controversial issues .

Thus, the primary aim of the present retrospective multicentric study is to evaluate intra and peri-operatory (< 30 days) and post-operative (> 30 days) morbidity and mortality rates of patients undergone LSG, and the correlation of the latter rates with different surgical measures. Secondary aim is to evaluate the strategy for the treatment of the complication, and if there is a correlation between morbidity/mortality and volume of the Bariatric Center

Read the detailed description

This study is a retrospective multicenter trial conduct from January 2015 to December 2020 in 10 centers. All the procedures were performed by the (---- number of surgeons). Morbid obesity was preoperatively diagnosed according to the International Federation for Surgery of Obesity (IFSO) guidelines. Patients were collected in a electronic database and categorized according to the following parameters:

  • Distance of resection margin from the pylorus (>5 cm / <5 cm)
  • Bougie size (>34 French, <34 French)
  • Distance of resection margin from the gastroesophageal junction (>…cm/<...cm)
  • Staple line reinforcement (Yes/No - If yes, the reinforcement technique will be reported)
  • Intraoperative leak testing (Yes/No - If yes, the test used will be reported)
  • Number and size of trocar used and access closure technique (Yes/No - If yes, the technique will be reported) The study protocol was approved by the regional Ethics Committee. 2.2 Inclusion criteria Inclusion criteria were morbid obesity defined as BMI 40 kg/m2 or BMI>35 with comorbidity and age between 25-60 years old. Obesity-related comorbidities included Type 2 Mellitus Diabetes (T2MD), hypertension, hyperlipidemia, bronchial asthma, osteoarthritis and degenerative joint disease.

2.3 Exclusion Criteria Patients with endocrine disorders causing obesity (as hypothyroidism and Cushing disease), pregnancy or lactation, psychiatric illness, or recent diagnosis of malignancy, inflammatory bowel disease, Barrett ́s esophagus, and GERD with esophagitis scored as or greater than grade B, a large hiatal hernia (>3 cm) were excluded from the study.

2.4 Study Outcomes The primary aims of the present retrospective multicentric study is to evaluate intra and peri and post operatory morbidity and mortality rates (< 30 and >30 days) of patients undergone Laparoscopic Sleeve Gastrectomy, and the correlation of the latter rates with different surgical measures. Secondary aims is to evaluate the strategy for the treatment of the complication, and if there is a correlation between morbidity/mortality and the volume of the Bariatric Center.

2.6 Blinding Process Physicians and staff who will collect the data and those who will evaluate the endpoints will all be unaware of the patients allocation. Patients will be collected in an electronic database with consecutive numbers without the possibility of identifying the center of origin until the final evaluation of the study endpoints. As the blinding process for the operating surgeons is not feasible, they are not involved in data collection and evaluation of results.

2.5 Pre-operative evaluation Preoperative evaluation included anthropometric measurements (height in cm, weight in kg, Body Mass Index (BMI) in kg/m2), comorbidity evaluation [Glycated Hemoglobin(A1c), C-peptide, stimulated C-peptide, Electrocardiography (ECG), echocardiography, lower limbs US color-doppler study, thyroid function profile]. All patients were evaluated for the presence/absence of Gastro Esophageal Reflux Disease before surgery through a preoperative upper endoscopy with an eventual esophageal biopsy. The presence of helicobacter pylori is also investigated with for a rapid urease test on an antral specimen.

2.7 Surgical Technique The patient is placed in a split leg position with the surgeon located in between the patient's legs. Closed pneumoperitoneum was established using our standard technique of Verres needle insufflation in Palmer site and optical insertion of a 12-mm port at a supraumbilical site (10-15 cm from umbilicus) Two further 15-mm and 12-mm ports were placed respectively in the left and right ipocondrum as working ports. A subxiphoid track was created using a 5-mm port for placement of a liver retractor. In patients with higher body mass index who have severe visceral obesity, additional trocars can be added for retraction of the omentum or big fatty livers, to optimize the exposure to reach the left crus. Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. Researchers use a 36French bougie or --------- Researchers have chosen cartridges Black at the antrum level and finished with a purple cartridge. Researchers always checked the posterior wall before firing. Once Researchers have reached the proximal stomach, the stapler has to be positioned 1 cm lateral to the left of the angle of His to avoid inclusion of esophageal tissue. Methylene blue test is performed routinely.

2.8 Post-operative evaluation Regarding the primary endpoints, intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded. Perioperative complications (<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment. Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment Regarding the secondary endpoint, in case of gastric fistula onset its diagnosis method (clinical, instrumental) and its management (timing, surgical or endoscopic - endoprosthesis, pigtails, clips-) or both) are collected and recorded. In case of postoperative bleeding, its diagnosis method (clinical, instrumental) and its management (timing, Surgical, medical) are collected and recorded.

3.6 Statistical Analysis Continuous data are expressed as median and interquartile (25-75th) range or mean and Standard Deviation (SD), unless otherwise indicated. Differences between preoperative and postoperative parameters were compared by Wilcoxon paired rank test. Median time of follow-up was estimated using the Kaplan-Meier method. Multivariable analysis was conducted through a forward-backward stepwise Cox regression based on Akaike Information Criterion (AIC) considering age, gender, % Excess Weighth Loss, Body Mass Index and treatment.

For all tests, the cut-off for statistical significance was set at p= 0.05. Statistical analysis was performed using R v3.5.0.

Conditions
Morbid Obesity
Being tested
Sleeve Gastrectomy
Keywords
Bariatric surgery, morbidity and mortality
Medical subject headings
Obesity, Morbid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sleeve GastrectomyProcedure or surgery

    Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.

Study groups in NCT04643262
Study groupRoleWhat they receive
Intraoperative morbidity and mortalityIntraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.
Receives: Procedure: Sleeve Gastrectomy
peri-operative morbidity and mortality (<30 days)Perioperative complications (<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.
Receives: Procedure: Sleeve Gastrectomy
Post-operative morbidity and mortality (>30 days)Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment
Receives: Procedure: Sleeve Gastrectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraoperative complications

    splenectomy, bleeding, positive leak test if performed

    Measured: time 0

  2. Perioperative complications

    Mortality

    Measured: up to 4 weeks from surgery

  3. Perioperative complications

    Morbidity:( leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) < 30 days

    Measured: up to 4 weeks from surgery

  4. Postoperative complications

    Mortality

    Measured: up to 6 months

  5. Postoperative complications

    Morbidity: (leak, embolism, Incisional trocar hernia) >30 days

    Measured: up to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Nov 2020
  2. Study start1 Jan 2015
  3. Primary completion1 Jan 2015
  4. Study completion30 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
10,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04643262
Sponsor's protocol ID
18112010
Acronym
PSICHE
Status last verified
Jul 2021
First submitted
13 Nov 2020
Last updated
21 Jul 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Morbid Obesity, run by Azienda Sanitaria Locale Napoli 2 Nord.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraoperative complications (time frame: time 0). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in